1st Quarter - Report

THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. State opioid response (SOR) Grant funding. Substance Abuse and Mental Health Block Grant (SABG) funding.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: SENATE

Health Issues HCR

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. State opioid response (SOR) Grant funding. Substance Abuse and Mental Health Block Grant (SABG) funding.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.